Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic tools minimizing the need for invasive procedures or that add information to histologic data are important in novel management strategies for the growing epidemic of NAFLD. We describe an "omics" approach to detecting a reproducible signature of lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in a double-blinded study of patients with different stages of NAFLD that involves profiling liver biopsies, plasma, and urine samples. Using linear discriminant analysis, a panel of 20 plasma metabolites that includes glycerophospholipids, sphingolipids, sterols, and various aqueous small molecular weight components involved in cellular metabolic pathways, can be used to differentiate between NASH and steatosis. This identification of differential biomolecular signatures has the potential to improve clinical diagnosis and facilitate therapeutic intervention of NAFLD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Little evidence is available on circulating phosphatidylinositol and phosphatidylserine, which have been found to be higher in MASL(101, 102) or only in MASH (phosphatidylinositol).108”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“High levels of plasma ceramides are correlated with the severity of MASLD and reflect hepatic ceramide accumulation.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Plasma saturated/unsaturated fatty acid TAGs have been found to be elevated,102,103 and associated with IR11,104 in individuals with MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Patients with MASH have 20% higher ceramide concentrations compared to healthy individuals.100,102,104,117”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“A few studies have also investigated circulating lipidomic species in patients with advanced forms of MASH (F3), fibrosis, and cirrhosis, showing an increase in circulating levels of some ceramides (d18:1/20:0, d18:1/22:0, d18:1/23:0, d18:1/24:1, d18:1/24:0) and a decrease in hexosylceramide,115 some glucosylceramide (d18:1/24:1, d18:1/26:1, 18:1/26:0), SM, PC, LPC, and phosphatidylinositol94,102”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Lipidomics reveals a remarkable diversity of lipids in human plasma
Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m009449 · Cited by 1,341
Self-citation
Cited by
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C., Chevet, E., & Bailly-Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 944
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
Wong, V. W.-S., Adams, L. A., de Lédinghen, V., Wong, G. L.-H., & Sookoian, S. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0014-9 · Cited by 614
Pierantonelli, I., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 460
Seidman, J. S., Troutman, T. D., Sakai, M., Gola, A., Spann, N. J., Bennett, H., Bruni, C. M., Ouyang, Z., Li, R. Z., Sun, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.001 · Cited by 443
“A corresponding increase in desmosterol was reported in livers of human subjects with NASH and cirrhosis (Gorden et al., 2015).”
BackgroundSelf-citation
Metadata
- Authors
- Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., Duan, J., Sullards, M. C., Leiker, T. J., Barkley, R. M., Quehenberger, O., Armando, A. M., Milne, S. B., Mathews, T. P., Armstrong, M. D., Li, C., Melvin, W. V., Clements, R. H., Washington, M. K., Mendonsa, A. M., Witztum, J. L., Guan, Z., Glass, C. K., Murphy, R. C., Dennis, E. A., Merrill, A. H., Russell, D. W., Subramaniam, S., & Brown, H. A.
- Affiliations
- Vanderbilt University Medical Center (US)
- University of California San Diego (US)
- The University of Texas Southwestern Medical Center (US)
- Georgia Institute of Technology (US)
- University of Colorado Denver (US)
- Duke Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Subramaniam, Shankar
- Brown, H.Alex
- ORCID
- Fahy, Eoin
- Maurya, Mano R.
- Gupta, Shakti
- Spann, Nathanael J.
- McDonald, Jeffrey G.
- Duan, Jingjing
- Barkley, Robert M.
- Quehenberger, Oswald
- Armando, Aaron M.
- Milne, Stephen B.
- Mathews, Thomas P.
- Washington, M.Kay
- Witztum, Joseph L.
- Guan, Ziqiang
- Glass, Christopher K.
- Murphy, Robert C.
- Dennis, Edward A.
- Merrill, Alfred H.
- Russell, David W.
- Subramaniam, Shankar
- Brown, H.Alex
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 56
- Issue
- 3
- Pages
- 722-736
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4340319
- OpenAlex
- W2134541386
- Cited by
- 372
- References
- 73
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 38 · 2023: 34 · 2022: 34 · 2021: 56 · 2020: 42 · 2019: 32 · 2018: 25 · 2017: 20 · 2016: 21 · 2015: 11
- FWCI
- 20.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2040 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL106579)
- National Institute of Mental Health (T32MH093366)
- National Institute of General Medical Sciences (U54GM069338, R24GM107784, GM U54 069338)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK074868, P30DK058404)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, steatosis, disease progression, lipidomics, plasma metabolites, biomarkers, glycerophospholipids, sphingolipids, sterols, liver biopsy, diagnostic signature, NAFLD staging
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Biomarkers, Polymorphism, Single Nucleotide, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. https://app.cochat.ai/papers/10.1194/jlr.p056002
- The paper
- Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., Duan, J., Sullards, M. C., Leiker, T. J., Barkley, R. M., Quehenberger, O., Armando, A. M., Milne, S. B., Mathews, T. P., Armstrong, M. D., . . . Brown, H. A. (2015). Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Journal of Lipid Research. https://doi.org/10.1194/jlr.p056002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.